{"id":37904,"date":"2018-08-28T10:51:25","date_gmt":"2018-08-28T08:51:25","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=37904"},"modified":"2018-08-28T10:51:25","modified_gmt":"2018-08-28T08:51:25","slug":"scadenza-brevetti-accordo-tra-mise-e-ministero-della-salute","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/scadenza-brevetti-accordo-tra-mise-e-ministero-della-salute\/","title":{"rendered":"Patent expiry, agreement between Mise and the Ministry of Health"},"content":{"rendered":"<h4 class=\"site-block__title\">The need to access structural information on product protection certificates emerged from the technical table on pharmaceutical governance and medical devices set up in early August<\/h4>\n<p><span class=\"post-author\">Of <a title=\"Articles written by: Aboutpharma Online editorial staff\" href=\"https:\/\/www.aboutpharma.com\/blog\/author\/redazioneaboutpharma-com\/\" rel=\"author noopener\" target=\"_blank\">Aboutpharma Online editorial staff<\/a><\/span> &#8211; <a href=\"https:\/\/www.aboutpharma.com\/blog\/2018\/08\/27\/scadenza-brevetti-accordo-tra-mise-e-ministero-della-salute\/\" target=\"_blank\" rel=\"noopener\">August 27, 2018 \u2013 AboutPharma <\/a><\/p>\n<p>On the subject of the patent expiry there is an agreement between Mise and the Ministry of Health. The purpose of the request made by Giulia Grillo&#039;s dicastery was to facilitate access and consultation of the patent databases (which contain deadlines and certificates of complementary protection).<\/p>\n<h2>Speed up processes<\/h2>\n<p><a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/08\/brevetto-farmaci-durata.gif\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-37906 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2018\/08\/brevetto-farmaci-durata.gif\" alt=\"\" width=\"400\" height=\"320\" \/><\/a>The request arises from the need of the technical offices of AIFA and the Regions to be able to access this precious data in an organic and timely manner. This pressing need emerged at the <a href=\"https:\/\/www.aboutpharma.com\/blog\/2018\/08\/02\/ministero-si-e-costituito-il-tavolo-tecnico-sui-farmaci-e-dispositivi-medici\/\" target=\"_blank\" rel=\"noopener\">Technical table on pharmaceutical governance and medical devices recently set up at the Ministry of Health<\/a>. According to experts, accelerated processes are needed to be able to deal with a periodic update of the national pharmaceutical formulary. In fact, equivalent medicines, as known, cannot be classified by the National Health Service with effect prior to the expiry date of the patent or the complementary protection certificate.<\/p>\n<h2>Fast times<\/h2>\n<p>&quot;It is quite evident that the possibility of finally being able to acquire the data in question quickly - wrote the Minister of Health, Giulia Grillo, to the Minister of Economic Development, Luigi Di Maio - assumes importance and a strategic impact for the purposes of classification of medicines by the National Health Service. For this, I thank the Mise for having filled a historic information gap, allowing us at this point to proceed with greater certainty and with a precise picture of the situation&quot;.<\/p>\n<p>Related news: <a href=\"http:\/\/www.sefap.it\/web\/upload\/GIFF_2013_5_30_34.pdf\" target=\"_blank\" rel=\"noopener\">Community and national rules on generics<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Dal Tavolo tecnico sulla governance farmaceutica e sui dispositivi medici costituitosi a inizi agosto \u00e8 emersa la necessit\u00e0 di accedere a informazioni strutturali sui certificati di protezione dei prodotti di Redazione Aboutpharma Online &#8211; 27 agosto 2018 &#8211; AboutPharma Sul tema della scadenza brevettuale c\u2019\u00e8 un accordo tra Mise e ministero della Salute. Scopo della &hellip;<\/p>","protected":false},"author":4,"featured_media":37908,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[31,41,26],"class_list":["post-37904","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-generici","tag-leggisentenze","tag-spesa-farmaceutica"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/37904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=37904"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/37904\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/37908"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=37904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=37904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=37904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}